View More Recent Stories
-
Neurocrine Biosciences (NBIX) Tops Q3 EPS by 29c, Beats on Revenue; Offers FY24 Revenue Guidance
-
Oppenheimer Reiterates Outperform Rating on Neurocrine Bio. (NBIX)
-
Piper Sandler Reiterates Overweight Rating on Neurocrine Bio. (NBIX)
-
Raymond James Resumes Neurocrine Bio. (NBIX) at Outperform
-
RBC Capital Reiterates Sector Perform Rating on Neurocrine Bio. (NBIX)
-
Neurocrine Biosciences (NBIX) Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
-
Mizuho Reiterates Neutral Rating on Neurocrine Bio. (NBIX)
-
BMO Capital Reiterates Market Perform Rating on Neurocrine Bio. (NBIX)
-
Neurocrine Biosciences (NBIX) Provides Update on ERUDITE Phase 2 Data for Luvadaxistat
-
H.C. Wainwright Reiterates Buy Rating on Neurocrine Bio. (NBIX)
-
Piper Sandler Upgrades Neurocrine Bio. (NBIX) to Overweight
-
Neurocrine Bio. (NBIX) PT Lowered to $128 at BMO Capital
-
TD Cowen Reiterates Buy Rating on Neurocrine Bio. (NBIX)
-
Neurocrine shares slump on Phase 2 results for schizophrenia treatment
-
Neurocrine Biosciences (NBIX) Reports Positive Phase 2 Data for NBI-1117568
-
Neurocrine Bio. (NBIX) PT Raised to $189 at Jefferies
-
Neurocrine Bio. (NBIX) PT Raised to $190 at H.C. Wainwright
-
Neurocrine Bio. (NBIX) PT Raised to $158 at Citi
-
Neurocrine Biosciences (NBIX) Tops Q2 EPS by 50c
-
Neurocrine Biosciences (NBIX) Launches INGREZZA SPRINKLE Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
-
Neurocrine Biosciences (NBIX) Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
